loading...| Preferred Name |
Dexrazoxane Hydrochloride |
|
| Synonyms |
|
|
| Definitions |
The hydrochloride salt of a bisdioxopiperazine with iron-chelating, chemoprotective, cardioprotective, and antineoplastic activities. After hydrolysis to an active form that is similar to ethylenediaminetetraacetic acid (EDTA), dexrazoxane chelates iron, limiting the formation of free radical-generating anthracycline-iron complexes, which may minimize anthracycline-iron complex-mediated oxidative damage to cardiac and soft tissues. This agent also inhibits the catalytic activity of topoisomerase II, which may result in tumor cell growth inhibition. |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C66945 |
|
| Accepted_Therapeutic_Use_For |
severe side effects caused by certain types of chemotherapy including extravasation, cardiac side effects by doxorubicin. |
|
| ALT_DEFINITION |
A drug used to treat severe side effects caused by certain anticancer drugs. It is used under the brand name Totect to treat the toxic effects of an anticancer drug that leaks from a vein into surrounding tissue and causes tissue damage. It is also used under the brand name Zinecard to reduce heart damage in women given doxorubicin for breast cancer that has spread. Dexrazoxane hydrochloride is also being studied in the treatment of cancer. It is a type of cardioprotective agent, a type of chemoprotective agent, and a type of topoisomerase inhibitor. |
|
| CAS_Registry |
149003-01-0 |
|
| CHEBI_ID |
CHEBI:50224 |
|
| Chemical_Formula |
C11H16N4O4.HCl |
|
| code |
C66945 |
|
| Contributing_Source |
CTRP FDA |
|
| definition |
The hydrochloride salt of a bisdioxopiperazine with iron-chelating, chemoprotective, cardioprotective, and antineoplastic activities. After hydrolysis to an active form that is similar to ethylenediaminetetraacetic acid (EDTA), dexrazoxane chelates iron, limiting the formation of free radical-generating anthracycline-iron complexes, which may minimize anthracycline-iron complex-mediated oxidative damage to cardiac and soft tissues. This agent also inhibits the catalytic activity of topoisomerase II, which may result in tumor cell growth inhibition. |
|
| Display_Name |
Dexrazoxane Hydrochloride |
|
| FDA_UNII_Code |
5346058Q7S |
|
| Has_Free_Acid_Or_Base_Form | ||
| in_subset |
http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C177537 http://purl.obolibrary.org/obo/NCIT_C176424 http://purl.obolibrary.org/obo/NCIT_C116977 http://purl.obolibrary.org/obo/NCIT_C116978 http://purl.obolibrary.org/obo/NCIT_C128784 |
|
| Is_Value_For_GDC_Property | ||
| label |
Dexrazoxane Hydrochloride |
|
| Legacy Concept Name |
Dexrazoxane_Hydrochloride |
|
| Maps_To |
Dexrazoxane Hydrochloride |
|
| NCI_Drug_Dictionary_ID |
39485 |
|
| PDQ_Closed_Trial_Search_ID |
39485 |
|
| PDQ_Open_Trial_Search_ID |
39485 |
|
| Preferred_Name |
Dexrazoxane Hydrochloride |
|
| prefixIRI |
NCIT:C66945 |
|
| prefLabel |
Dexrazoxane Hydrochloride |
|
| Semantic_Type |
Pharmacologic Substance |
|
| UMLS_CUI |
C0982118 |
|
| subClassOf |